Background: Latent autoimmune diabetes in adults (LADA) exhibits significant clin-
accordance with Helsinki guidelines, an informed consent was provided by all subjects who participated in the study. The protocol was approved by the research ethics committee of the Second Xiangya Hospital of Central South University. 
| CONTROL SUBJECTS
A group of 1065 control subjects were recruited from 2 cross-sectional surveys included the Railway System Staff Investigation and the LADA China multicenter investigation. 7, 17 All subjects had normal glucose tolerance and no family history of diabetes. Genotyping for HLA-DQA1 and HLA-DQB1 of control subjects was utilized in this study.
| CLINICAL CHARACTERISTICS AND BIOCHEMICAL MEASUREMENTS
At admission, anthropometric data including age at disease onset, duration of disease, sex, body weight, height, waist circumference, hip circumference, blood pressure, waist-hip ratio, and body mass index were obtained. types tested with Bonferroni correction (denoted as P c ). Significance level α was adjusted for α′ = α / [n × (n − 1) / 2] (n = 3, groups) in the pairwise rate comparison among 4 groups. P < α = 0.05 or P c < 0.05 or P < α′ was considered significant. Analysis of covariance was used to adjust the potential confounding variable GADA titre.
10 | RESULTS
| Comparative features among 3 groups
The proportion of E-LADA patients accounted for 23.3% (135/579) of the overall LADA cohort. Clinical, biochemical, and metabolic characteristics of the study participants are shown in Table 1 . The clinical phenotype of overall LADA patients was significantly different from overall T2D patients (summarized in Supplementary Table 1 
| Clinical characteristics of E-LADA stratified by BMI, GADA titres, and FCP
Analysis of the data in E-LADA patients stratified by BMI showed that FCP and 2-hour postprandial C-peptide levels were higher in higher BMI group (BMI ≥ 25.0 kg/m 2 ) than those in leaner group (BMI < 25.0 kg/m 2 , all P < .05), whereas in E-LADA with higher BMI, the FCP level was significantly higher than that in total E-T2D (P < .01, 
| Assessment of islet beta cell function and insulin resistance levels
To assess islet beta cell function, we determined both fasting and 2-hour postprandial C-peptide levels in study participants. As shown in 
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Fasting BS (mmol/L) 8.9 ± 3.9 9.6 ± 4.0 10. patients (both P < .01). However, both C-peptide levels in E-LADA group were similar to E-T2D group. E-LADA patients were more insulin resistant than Y-LADA patients as assessed by HOMA-IR (P < .01). The insulin resistance levels were similar between E-LADA and E-T2D.
| E-LADA features according to autoantibodies
In E-LADA patients, 91.2% were positive for GADA, 26.1% for IA-2A, and 13.6% of patients were positive for both 2 autoantibodies. The frequencies of autoantibody positivity, either alone or in combination, were similar between E-LADA and Y-LADA patients (Supplementary table 4) . We further analysed the titre of GADA in E-LADA patients based on age group (Figure 4) . Elderly LADA patients have more proportion of low titre GADA and lower GADA titres compared to Y-LADA patients aged <40 years (both P < .01).
| Determination of susceptible HLA DQA1-DQB1 haplotypes
We have previously identified that certain HLA DQA1-DQB1 haplotypes are involved in the pathogenesis of LADA, 11 and as such, we compared the DQA1-DQB1 haplotype frequencies in E-LADA patients to those in Y-LADA, overall T2D, and control subjects (Table 2) . Overall LADA patients (including both E-LADA and Y-LADA) had higher frequencies for the DQA1*05-DQB1*0201, DQA1*03-DQB1*0401, DQA1*0201-DQB1*0201, and DQA1*0102-DQB1*0604 haplotypes than control subjects (all P c < .01). The frequency for the DQA1*0102-DQB1*0604 haplotype in LADA, E-LADA, and T2D patients was significantly higher than that in controls, respectively (all P c < .001), while the frequencies for haplotypes DQA1*05-DQB1*0201, DQA1*03-DQB1*0401, and DQA1*0201-DQB1*0201 were significantly higher in both LADA and Y-LADA FIGURE 2 Metabolic characteristics of E-LADA patients stratified with fasting C-peptide compared with E-T2D. * P < .05, ** P < .01; FCP ≤400 denotes E-LADA patients with FCP ≤400 pmol/L, FCP >400 denotes E-LADA patients with FCP >400 pmol/L. BMI, body mass index; FCP, fasting C-peptide compared with that of control subjects. The frequency for haplotype DQA1*03-DQB1*0303 was significantly higher in Y-LADA patients but not in LADA and E-LADA patients compared with that of control subjects (all P c < .01).
| DISCUSSION
Latent autoimmune diabetes in adults is probably the most prevalent form of autoimmune diabetes in general. 20 It is characterized by genetic, phenotypic, and humoral heterogeneity, encompassing different degrees of insulin resistance and autoimmunity. 13 However, the major characteristics of LADA are mainly focused on 3 points: presence of islet autoantibodies, age at diagnosis of at least 30 years, and insulin independence for at least 6 months after diagnosis. 21 Much evidence have shown that a lower body mass index, waist-hip ratio, total cholesterol, and triglyceride levels and higher HDL-cholesterol in LADA than those in patients with T2D. But some scholars have found that LADA and T2D were not distinct disease entities beyond the differences explained by BMI. 22 The clinical phenotype of patients with LADA also varies substantially with GADA titre. High-titre GADA patients tend to be more similar to classic type 1 diabetes. Low-titre GADA patients are phenotypically more similar to those with T2D. 23 These differences are also reflected by the metabolic syndrome, which is more prevalent in T2D than LADA, and more prevalent in low-titre than high-titre GADA patients 20 These studies have showed LADA exhibited significant clinical heterogeneity.
Some findings of this study are mainly confirmatory of previous observations from LADA patients of different ethnicity. 3, 23 Nevertheless, the data in this study were conducted specifically in a Chinese population, while previous studies were conducted in European people. It is crucial to study clinical features of diabetes and LADA in different ethnic groups. 2, 4 The present study demonstrates that age of onset of LADA significantly contributes to the clinical heterogeneity.
Patients with E-LADA had significantly more components or characteristic of metabolic syndrome than those with Y-LADA. But although E-LADA patients have the strikingly different lipid profiles, it tends to have similar metabolic syndrome prevalence as compared with E-T2D
patients. These data indicated that the characteristics of metabolite profile in E-LADA are more close to E-T2D.
Previous studies have confirmed that metabolic syndrome is prevalent in LADA patients; however, it is less prevalent compared with T2D patients. 14 Consistent with this, in our study, up to 59.2% of E-LADA patients have metabolic syndrome. This prevalence was seemingly higher than the rate of 41.9% reported in European LADA patients 14 and the rate of 31.0% reported in another Chinese study. 24 Analysis of the data in E-LADA patients stratified by GADA titre showed that more components of metabolic syndrome were evident in E-LADA patients with low titre of GADA.
Furthermore, the clinical phenotype within E-LADA patients also varies largely depending on islet cell function. E-LADA patients with better FCP level have more components or prevalence of metabolic syndrome, which is phenotypically more similar to patients with T2D, as compared to patients with worse FCP. These mean that E-LADA with different characteristics should be differently treated.
A large body of evidence have shown that LADA patients tend to have a more pronounced loss of C-peptide and an increased likelihood of insulin treatment compared with T2D patients. 7, 15, 25 In our study, both fasting and 2-hour postprandial C-peptide levels were significantly higher in E-LADA patients as compared to Y-LADA patients, but were similar to E-T2D. This observation can be partially explained by the fact that E-LADA patients have less proportion of high-titre GADA and higher GADA titres. It was showed that high-titre GADA was associated with more severe autoimmunity resulting in more prominent traits of insulin deficiency. 23 We also found that patients with E-LADA displayed more serious insulin resistance level than those with Y-LADA patients but were not significant compared with patients with E-T2D, making their clinical presentation more similar to E-T2D. Hence, E-LADA was more similar to T2D than Y-LADA. Previously, Lohmann et al observed that patients with lower BMI show a more aggressive disease, which can lead to earlier beta-cell exhaustion. 26 In accordance with this study, we observe that E-LADA patients with lower BMI tend to have a lower FCP and 2-hour postprandial C-peptide levels. Higher BMI is usually associated with higher C-peptide. From this point of view, the finding that E-LADA with higher BMI has higher C-peptide than total E-T2D with lower BMI is not difficult to explain. These observations also indicate that E-LADA patients with leaner physique have poorer residual beta-cell function than patients with a fatter body.
Currently, GADA is thought to be the most sensitive and specific biomarker in the diagnosis of LADA. 27 In this study, GADA was also the most frequent islet autoantibody in both E-LADA and Y-LADA patients. Hence, we recommended that detection of GADA autoantibody alone is sufficient when screening for patients with LADA. Although the presence of multiple islet-related autoantibodies provided more information than either assay on its own, the frequencies of both islet autoantibodies combined were low. In view of this low prevalence of combined autoantibodies, screening for additional islet autoantibodies are unlikely to be cost-effective in T2D patients diagnosed after the age of 60 years. background that E-LADA may share genetic characteristics with T2D.
As shown by Buzzetti et al, the differences in clinical features may be driven by GADA titre. 23 In this study, we indeed found that a significant difference in GADA autoantibody titre was seen between E-LADA and Y-LADA. Therefore, the differences in all analysis between E-LADA and Y-LADA were reanalysed by adjusting for GADA titre with analysis of covariance. All the significant differences between E-LADA and Y-LADA after adjusting for GADA titre are still significant (Supplementary table 5) .
We acknowledge some limitations of our investigation. First, it is cross-sectional, allowing the differences to be compared from the clinical state only at the time of observation. Difference between E-LADA and T2D in islet beta cell function was not assessed by the follow-up which was planned to further studies for the next stage. Another limitation of this study is that although there are a substantial number of LADA cases, the number of E-LADA patients, especially for genetic studies, was relatively small, which leads us to treat the significance levels of the analyses with caution and to emphasize the need for replication in other populations.
Finally, we did not determine the HLA-DR typing. Clearly, if we had conducted HLA-DR typing in addition to the DQA1-DQB1 analysis, it would have allowed greater insight into the LADA risk associations.
In conclusion, patients with E-LADA have better residual beta-cell function, a higher prevalence of metabolic syndrome, similar proportion of islet autoantibodies detection, and strikingly different HLA-DQ gene background as compared with patients with Y-LADA. E-LADA patients tend to have similar metabolic syndrome prevalence, comparable C-peptide levels and insulin resistance levels, and sharing a kind of genetic characteristic in comparison with T2D, making their clinical presentation more similar to T2D. These phenotypes seemingly present a continuous spectrum from Y-LADA, through E-LADA, to E-T2D, which deserve further investigation. To our knowledge, this study is the first study to characterize E-LADA in a fairly number of total LADA population. These clinically distinct features could potentially help physicians take better clinical management for these patients with E-LADA. Our study findings also expand on knowledge about LADA and enrich the study about subgroups of diabetes or diabetes as a continuous spectrum. However, it is impossible to accurately distinguish E-LADA from T2D on clinical features because of overlapping for some clinical parameters. Much more researches are required to focus on the characterization of LADA or E-LADA patients.
